Scientists hunt for clues to predict immunotherapy success in stomach cancer
NCT ID NCT05508399
First seen Jan 05, 2026 · Last updated May 20, 2026 · Updated 20 times
Summary
This study looked at 28 people with stomach or gastroesophageal junction cancer to find biological markers that can predict how well a combination of the immunotherapy drug tislelizumab and chemotherapy works before surgery. Researchers analyzed RNA from tumor samples and built a model to forecast treatment response. The goal is to help doctors choose the best treatment for each patient in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED GASTRIC ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Xijing Hospital of Digestive Diseases
Xi'an, Shaanxi, 710000, China
Conditions
Explore the condition pages connected to this study.